CLINICAL_TRIALS
trial_result
· 2019-05-01
Clinical Trial Update: IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab [Phase 4]
Summary
Phase 4 trial update on intravitreal anti-angiogenic inhibitor (IAI) for persistent diabetic macular edema after bevacizumab and ranibizumab.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Snippet
Sponsor: Southeast Retina Center, Georgia | Conditions: Diabetic Macular Edema | Phase 4 | Status: COMPLETED | Results posted: 2019-05-01